MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

IRVINE, CA, and HERSTAL, BELGIUM – March 21, 2017 – MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx™ for Prostate Cancer test available to Lab21 Clinical Laboratory’s urology clients in the United Kingdom.

MDxH-Lab 21 agreement PR ENG